Establishment of a murine model of breast cancer expressing human epidermal growth factor receptor 2 (4T1-HER2)

Vahid Khaki Bakhtiarvand,Khadijeh Ramezani-Ali Akbari,Fatemeh Sadri,Farzaneh Notash Haghighat,Mohammad Hojjat-Farsangi,Fazel Shokri,Mahmood Jeddi-Tehrani,Mahdi Shabani
DOI: https://doi.org/10.4103/jcrt.jcrt_1303_22
2024-04-01
Abstract:Aim: Although people with HER2-positive breast cancer benefit from approved HER2-targeted therapy, acquiring resistance to the therapies occurs. Animal models can play a part in gaining a deep understanding of such a process and addressing questions concerning developing and improving immunotherapy approaches. Materials and methods: To develop such a model, we transfected murine 4T1 cells with the pCMV6-Neo-HER2 construct and evaluated HER2 expression and its effects on the established cell line behavior in vitro and in vivo. Results: Data illustrated that human HER2 protein was expressed on isolated 4T1-HER2 clones in vitro and in vivo. Except for proliferation over 48 hours, such expression did not change 4T1-HER2 characteristics compared to 4T1 in vitro. Notwithstanding the reduction in proliferation, the rate of tumorigenicity was 90% in challenged mice and Herceptin therapy significantly decreased tumors' growth and metastasis compared to the control group. Conclusion: We describe a murine model for HER2-positive breast cancer not only helping shed light on the mechanisms by which the tumor evades antitumor immunity but also playing a key role in making breast cancer more sensitive to novel immunotherapy modalities.
What problem does this paper attempt to address?